Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AK-OTOF by Akouos for Acute Sensorineural Hearing Loss: Likelihood of Approval
AK-OTOF is under clinical development by Akouos and currently in Phase II for Acute Sensorineural Hearing Loss. According to GlobalData,...
AK-OTOF by Akouos for Acute Sensorineural Hearing Loss: Likelihood of Approval
AK-OTOF is under clinical development by Akouos and currently in Phase II for Acute Sensorineural Hearing Loss. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's AK-OTOF?
AK-OTOF is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Acute Sensorineural...